Accrued Expenses and Other Liabilities

6 Months Ended

Jun. 30, 2024

Payables and Accruals [Abstract]

Accrued Expenses and Other Liabilities

10.Accrued Expenses and Other Liabilities.

Accrued expenses and other liabilities consist of the following (in thousands):

	June 30, 2024		December 31, 2023
Accrued preclinical and clinical trial expenses	$	516	$	1,015
Accrued professional fees		4,726		4,730
Accrued compensation and benefits		7,295		8,883
Accrued license fees		16,852		24,437
Accrued purchases		398		192
Operating lease liability		385		369
Accrued gross-to-net revenue liabilities*		40,507		6,877
Accrued income tax		15		729
Due to licensor		11,960		12,540
Accrued interest payable		1,376		1,031
Accrued charitable contributions		800		—
Other		372		465
Current accrued expenses and other liabilities		85,202		61,268
Lease liability – non-current		2,991		3,188
Due to licensor – non-current		1,230		2,497
Other – non-current		1,166		485
Non-current accrued expenses and other liabilities		5,387		6,170
Total accrued expenses and other liabilities	$	90,589	$	67,438

* During 2023, the Company sold FYCOMPA® through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA® is being sold and distributed through a 3PL organization.